Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT

• Status: Completed
• Trial end date: 2010-08-01

Summary

Due to evidence available both in terms of efficacy and safety of low molecular weight heparin, its use for the prevention of thromboembolic disease in cancer patients undergoing surgical intervention, and its extended use in higher doses for the prevention of recurrent thromboembolism in cancer patients with established thrombosis, with a view that the potential benefits for survival in cancer patients from low molecular weight heparin therapy comes because of a biological activity, the dose of 1mg/Kg (50% of the full treatment dose) for a period of 6 months coincident with 6 cycles of chemotherapy, has been chosen for this study.

• Phase: Phase 3

Details

• Lead Sponsor: Thrombosis Research Institute
• Treatments: Capecitabine; Carboplatin; Cisplatin; Enoxaparin; Epirubicin; Fluorouracil; Oxaliplatin